Xerys Funds invests €30m in Biolog-id

The company is currently valued at €150m and could surpass the €1bn mark by 2023, the strategy consulting firm Roland Berger estimated, according to a statement by Xerys.

The fresh capital will be used to accelerate Biolog-id's international development in North America, the Middle-East and Asia (in particular in China).

Biolog-id has received €50m to date from Xerys. The GP provided a round of growth capital funding for Biolog-id since 2009, according to a statement.

Company
Founded in 2005 and headquartered in Bernay, Biolog-id focuses on traceability and management of sensitive health products, including red blood cells, plasma, platelets and chemotherapy preparations. The firm employs 100 people and generates a €7m turnover, according to the French publication Les Echos.

Biolog-id is aiming to exceed €200m in turnover by 2023.

People
Biolog-id – Jean-Claude Mongrenier (president, founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France